A group of young people in rural Georgia are raising the alarm that quitting smoking could cause irreversible damage to their lungs.

Harris Health, a nonprofit hospital, is using an experimental drug to treat the disease.

It’s the latest in a long line of efforts by the university and other research labs to develop treatments for smoking.

But some doctors say that, while there’s a long way to go, the treatments have the potential to be far more effective than those already on the market.

A growing number of people in the U.S. are smoking.

In 2016, more than 22 million people in that country smoked, according to the Centers for Disease Control and Prevention.

Nearly three-quarters of adults aged 18 to 64 smoked in 2016, according the CDC.

The disease kills about 11,000 Americans a year, and experts say it could cause a global pandemic that could kill nearly three million people, according, the CDC says.

The group of teens are taking the risk seriously.

The drug is called Sativex, and it was developed by the University of Mississippi.

It’s an experimental treatment for nicotine dependence that was originally developed to treat people with lung cancer.

But scientists say Sativexs success in treating nicotine addiction is a result of research done by the group.

Researchers at the University School of Medicine in Mississippi found that the treatment worked better than conventional treatments.

The study, which was published in the journal Nicotine & Tobacco Research, showed that Sativexes nicotine replacement therapy (NRT) treatment reduced the amount of tar left in the lungs of people who had already smoked cigarettes.

But the treatment has not been tested on people with other types of smoking problems.

The University School says it plans to do so in the future.

“We have to do a lot more studies and we’ll know more in the next year or so, but I think it’s a very promising study,” said Dr. John Fauci, a professor of pediatrics and director of the university’s Center for Nicotine & Health and Prevention (CNHP).

“We’re hopeful that they can make a more definitive diagnosis and hopefully find a way to deliver that to people,” he said.NRT works by helping people to stop using nicotine by increasing the amount that they exhale.

But for some people, it can cause a problem.

For example, it might cause the body to store more of nicotine in the brain, which can cause it to become harder for the body and lungs to use.

“There are some things that we’ve been doing, and some things we’re not doing, to try and mitigate those,” said Sady Jones, a spokeswoman for the University Hospitals of South Carolina.

Nursing home for the past few years, Jones has seen some patients in the emergency department who were hooked on NRT.

She said it’s an expensive, time-consuming, and dangerous addiction treatment.

“It is not going to work,” Jones said.

“The medications that we’re currently testing are not going.

And they are going to be expensive.

So we’re going to have to wait and see.”

The treatment is meant to be given to people who smoke regularly, but they aren’t necessarily going to quit.

The drugs, called nasal patches, are administered by an injection into the nose.

The injection is then absorbed through the skin.

NRT is meant for people who can’t smoke cigarettes, but can still help with their dependence.

“I have patients who smoke cigarettes and have a very mild nicotine dependency,” Jones explained.

“But they have to smoke for two hours or more a day and then, I would say, the symptoms have come back.”

But many patients who quit smoking quit smoking after one week, which means they haven’t completely quit.

And some people have been able to quit for longer.

Nurse Mandy Bratcher, a medical coordinator at the hospital, said that while there have been many successful studies of NRT treatments, it’s not clear what the long-term effects will be.

She noted that many of the patients who have been given NRT had to quit because of the risk of addiction.

“They were trying to quit,” Bratcher said.

“So I think that the longer you have this medication that you’re taking, the more likely you are to relapse.”

The University School hopes to test NRT in a smaller group of people with more severe nicotine dependence, and they have been working to find ways to deliver the drugs in a safe and effective way.

The team is using a device that would be implanted in the nasal passages of the nostrils.

They hope that the nasal patch would provide a way for patients to inject nicotine into their bodies.

Dr. David Cogley, who is leading the study, says that while the drug is only tested on smokers, it should be administered to people with moderate or severe nicotine dependency.

He said it would be a good idea to have a larger group of smokers get the drug.

“What we need is a larger